VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Loncastuximab tesirine: a novel antibody-drug conjugate for DLBCL

Carmelo Carlo Stella, MD, PhD, of Humanitas Clinical and Research Center, Rozzano, Italy, discusses initial results of a Phase II study of loncastuximab tesirine, a novel antibody-drug conjugate targeting CD19, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter